CalciMedica, Inc.

CALC

Held by 1 specialist biotech fund

Fund Holdings

AI Signal

Deerfield's $8.6M entry into CalciMedica signals confidence in Ser-109, the company's lead spore-based therapeutic targeting recurrent *C.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 1,300,000Value: $8.6M

Deerfield's $8.6M entry into CalciMedica signals confidence in Ser-109, the company's lead spore-based therapeutic targeting recurrent *C. difficile* infection (rCDI), ahead of anticipated Phase 2b data. The position size is modest but notable given Deerfield's healthcare focus and suggests conviction in either clinical efficacy or M&A potential in a space where CDI treatments command premium valuations. Catalyst timing and data readout dates will be critical to monitor for near-term share movement.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: